7lus: Difference between revisions

(One intermediate revision by the same user not shown)

Line 1:

~~'''Unreleased structure'''~~

~~The entry~~ 7lus is ~~ON HOLD until Paper~~ Publication

==IgG2 Fc Charge Pair Mutation version 1 (CPMv1)==

== Structural highlights ==

<table><tr><td colspan='2'>[[7lus]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7LUS OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7LUS FirstGlance]. <br>

</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.45Å</td></tr>

<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>

<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7lus FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7lus OCA], [https://pdbe.org/7lus PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7lus RCSB], [https://www.ebi.ac.uk/pdbsum/7lus PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7lus ProSAT]</span></td></tr>

</table>

== Disease ==

[https://www.uniprot.org/uniprot/IGHG2_HUMAN IGHG2_HUMAN] Recurrent infections associated with rare immunoglobulin isotypes deficiency.

== Function ==

[https://www.uniprot.org/uniprot/IGHG2_HUMAN IGHG2_HUMAN]

== Publication Abstract from PubMed ==

Bispecific antibodies (Bispecifics) demonstrate exceptional clinical potential to address some of the most complex diseases. However, Bispecific production in a single cell often requires the correct pairing of multiple polypeptide chains for desired assembly. This is a considerable hurdle that hinders the development of many immunoglobulin G (IgG)-like bispecific formats. Our approach focuses on the rational engineering of charged residues to facilitate the chain pairing of distinct heavy chains (HC). Here, we deploy structure-guided protein design to engineer charge pair mutations (CPMs) placed in the CH3-CH3' interface of the fragment crystallizable (Fc) region of an antibody (Ab) to correctly steer heavy chain pairing. When used in combination with our stable effector functionless 2 (SEFL2.2) technology, we observed high pairing efficiency without significant losses in expression yields. Furthermore, we investigate the relationship between CPMs and the sequence diversity in the parental antibodies, proposing a rational strategy to deploy these engineering technologies.

~~Authors:~~ Sudom, A., Whittington, D., Garces, F., Wang, Z.

Next generation Fc scaffold for multispecific antibodies.,Estes B, Sudom A, Gong D, Whittington DA, Li V, Mohr C, Li D, Riley TP, Shi SD, Zhang J, Garces F, Wang Z iScience. 2021 Nov 15;24(12):103447. doi: 10.1016/j.isci.2021.103447. eCollection , 2021 Dec 17. PMID:34877503<ref>PMID:34877503</ref>

~~Description~~: ~~IgG2 Fc Charge Pair Mutation version 1 (CPMv1)~~

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>

[[Category: ~~Unreleased Structures~~]]

</div>

[[Category: ~~Whittington, D~~]]

[[Category: Garces, F]]

== References ==

[[Category: Sudom, A]]

[[Category: Wang, Z]]

__TOC__

</StructureSection>

[[Category: Homo sapiens]]

[[Category: Large Structures]]

[[Category: Garces F]]

[[Category: Sudom A]]

[[Category: Wang Z]]

[[Category: Whittington D]]

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 1: / Line 1: @@
-'''Unreleased structure'''
-The entry 7lus is ON HOLD  until Paper Publication
+==IgG2 Fc Charge Pair Mutation version 1 (CPMv1)==
+<StructureSection load='7lus' size='340' side='right'caption='[[7lus]], [[Resolution|resolution]] 2.45&Aring;' scene=''>
+== Structural highlights ==
+<table><tr><td colspan='2'>[[7lus]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7LUS OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7LUS FirstGlance]. <br>
+</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.45&#8491;</td></tr>
+<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7lus FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7lus OCA], [https://pdbe.org/7lus PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7lus RCSB], [https://www.ebi.ac.uk/pdbsum/7lus PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7lus ProSAT]</span></td></tr>
+</table>
+== Disease ==
+[https://www.uniprot.org/uniprot/IGHG2_HUMAN IGHG2_HUMAN] Recurrent infections associated with rare immunoglobulin isotypes deficiency.
+== Function ==
+[https://www.uniprot.org/uniprot/IGHG2_HUMAN IGHG2_HUMAN]
+<div style="background-color:#fffaf0;">
+== Publication Abstract from PubMed ==
+Bispecific antibodies (Bispecifics) demonstrate exceptional clinical potential to address some of the most complex diseases. However, Bispecific production in a single cell often requires the correct pairing of multiple polypeptide chains for desired assembly. This is a considerable hurdle that hinders the development of many immunoglobulin G (IgG)-like bispecific formats. Our approach focuses on the rational engineering of charged residues to facilitate the chain pairing of distinct heavy chains (HC). Here, we deploy structure-guided protein design to engineer charge pair mutations (CPMs) placed in the CH3-CH3' interface of the fragment crystallizable (Fc) region of an antibody (Ab) to correctly steer heavy chain pairing. When used in combination with our stable effector functionless 2 (SEFL2.2) technology, we observed high pairing efficiency without significant losses in expression yields. Furthermore, we investigate the relationship between CPMs and the sequence diversity in the parental antibodies, proposing a rational strategy to deploy these engineering technologies.
-Authors: Sudom, A., Whittington, D., Garces, F., Wang, Z.
+Next generation Fc scaffold for multispecific antibodies.,Estes B, Sudom A, Gong D, Whittington DA, Li V, Mohr C, Li D, Riley TP, Shi SD, Zhang J, Garces F, Wang Z iScience. 2021 Nov 15;24(12):103447. doi: 10.1016/j.isci.2021.103447. eCollection , 2021 Dec 17. PMID:34877503<ref>PMID:34877503</ref>
-Description: IgG2 Fc Charge Pair Mutation version 1 (CPMv1)
+From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-[[Category: Unreleased Structures]]
+</div>
-[[Category: Whittington, D]]
+<div class="pdbe-citations 7lus" style="background-color:#fffaf0;"></div>
-[[Category: Garces, F]]
+== References ==
-[[Category: Sudom, A]]
+<references/>
-[[Category: Wang, Z]]
+__TOC__
+</StructureSection>
+[[Category: Homo sapiens]]
+[[Category: Large Structures]]
+[[Category: Garces F]]
+[[Category: Sudom A]]
+[[Category: Wang Z]]
+[[Category: Whittington D]]